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Background: In cystic ﬁbrosis (CF), systemic inﬂammation and pulmonary infections sustain a catabolic response leading to fat free mass (FFM)
depletion.
Objectives: To investigate the association between recurrent pulmonary exacerbations and alteration in body composition in young adults with CF.
Methods: In a retrospective study we collected body composition data, obtained by DXA scan, on 85 young adults with CF (44 males, mean age
23 ± 4 years). Whole body and appendicular FFM were divided by height squared to obtain FFM indices (FFMI). Number of pulmonary
exacerbations occurred in the year preceding DXA scan were computed and patients were deﬁned as frequent exacerbators if they experienced
more than 2 pulmonary exacerbations/year. Body composition data were compared between frequent and infrequent exacerbators.
Results: Male patients classiﬁed as frequent exacerbators had lower total body bone mineral density (Z-score −1.44 ± 1.22 vs. −0.66 ± 0.92,
P = 0.033), whole body FFMI (18.0 ± 1.9 kg/m2 vs. 19.3 ± 1.4 kg/m2, P = 0.024) and appendicular FFMI (7.8 ± 1.0 kg/m2 vs. 8.8 ± 0.8 kg/m2
P = 0.004) compared to infrequent exacerbators. The reduced FFM found in frequent exacerbators was not uniformly distributed and involved
mainly appendicular FFM (mean difference: −11% compared to infrequent exacerbators, P = 0.016), whereas trunk FFM was not signiﬁcantly
affected by pulmonary exacerbations (mean difference −3% compared to infrequent exacerbators, P = 0.34). These differences were not found in
female patients.
Conclusions: Recurrent pulmonary exacerbations are associated with reduced appendicular FFM and bone mineral density in young male adults
with CF. The gender-dependent relationship between pulmonary exacerbations and body composition alteration needs to be further investigated.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Pulmonary exacerbations; Body composition; DXA1. Background
Cystic fibrosis (CF) is an inherited disease caused by
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1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.11.001and increased mucus thickness that damages various organs,
particularly the pancreas and lung. Over 80% of patients have
pancreatic insufficiency and are treated with pancreatic enzyme
replacement therapy. Lung disease is the leading cause of death
and is characterized by chronic bacterial infections and
systemic inflammation.
Achievement of an optimal nutritional status is universally
recognized as a relevant therapeutic goal in CF patients due to
its association with better pulmonary function [1].
Despite significant improvement in nutritional status over
the last decades, undernutrition remains an open issue in CF.by Elsevier B.V. All rights reserved.
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nutritional status of adult patients [1]. Nevertheless, BMI
is considered a good surrogate of adiposity in overweight
patients, but does not provide information on body composition
in patients with normal body size or lean subjects [2,3].
Fat free mass (FFM) depletion was reported in CF patients
and attributed to a catabolic state induced by low energy intake,
insulin deficiency and chronic inflammation that may impair
FFM and lead to a reduction in skeletal muscle mass,
inspiratory muscle wasting and loss of inspiratory muscle
function [4–8].
The aim of the study was to evaluate the relationship
between recurrent acute pulmonary exacerbations (APEs) and
altered body composition in young adults with CF. In addition
we verified if body composition indices obtained by soft tissue
analysis by DXA are associated with pulmonary function.
2. Methods
In a retrospective study we collected body composition, clinical
and sputum microbiology data from medical records of 85 young
adults with CF who had performed a DXA scan between January
2007 and June 2012. Patients who underwent lung transplantation
were excluded. The local ethics committee approved the study.
Patients were informed about the purpose of the study and gave
permission to include their clinical data in this research.
2.1. Pulmonary exacerbations
The number of APEs that had occurred during the year
preceding the DXA scan was derived from the clinical report of
each patient. Patients were defined as frequent exacerbators if
they had experienced more than 2 APEs the year before DXA
scan.
APE was defined as the need for additional antibiotic
treatment due to at least two of the following: change in sputum
volume or colour, increase in cough, dyspnea, malaise, fatigue
or lethargy, anorexia or weight loss, decrease in pulmonary
function by 10% or more or radiographic changes [9].
2.2. Dual energy X-ray absorptiometry (DXA)
Participants underwent whole-body DXA scanning (DXA
Hologic Discovery, Hologic, Waltham, USA), a technique that
is able to estimate fat mass (FM) and FFM by measuring the
X-ray attenuation of different tissue components. All DXA
scans were performed in the outpatient setting with the patients
in clinically stable condition (no symptoms suggesting APE).
Body composition was assessed by the three compartment
model (version 12.3), including FM, bone mineral content, and
lean tissue mass. FFM was calculated using the sum of the
estimates of lean tissue mass and bone mineral content. Bone
mineral density (BMD) was determined on total body.
Instrument calibration was obtained with a phantom
(including six fields of lucite and aluminium of varying
thickness and known absorptive properties) scanned as an
external standard. The whole-body DXA scans were performedand analysed by the same operator (MLB) according to the
same protocol throughout the whole study. The coefficients of
variation (CV) for total body FM and FFM were 2.9% and
1.7%, respectively. The CVs for FM and FFM of the main
subregions of total body were respectively: 2.4% and 1.6% for
trunk, 2.6% and 1.7% for legs and 3.1% and 2.6% for arms.
CVs were calculated in vivo with repositioning of subjects.
Age and gender-specific Z-scores of BMD were obtained with
reference to the BMD of a population of healthy age- and
sex-matched Italian young people. Whole body and appendicular
FFMwere divided by height squared to obtain FFM index (FFMI).
FFM depletion was defined as havingwhole body FFMI below the
5th centile for age and gender matched healthy subjects [10].
2.3. Anthropometry
Weight and height at the time patients had the DXA scan
were used to obtain the BMI. Patients were defined under-
weight if they had a BMI b 18.5 kg/m2. Males with a
BMI b 23 kg/m2 or females with a BMI b 22 kg/m2 were
considered below the CF Foundation (CFF) nutritional goal [1].
2.4. Sputum microbiology
Sputum microbiology data in the year preceding DXA scan
were collected. Chronic lung infections by Pseudomonas
aeruginosa, Burkholderia cepacia complex and Methicillin
Resistant Staphyloccus aureus were registered. Patients having
at least 4 cultures per year, at least half of which positive for
one of the previous mentioned bacteria were considered
chronically infected [11].
2.5. Pulmonary function
Pulmonary function tests were performed according to the
American Thoracic Society and European Respiratory Society
guidelines [12]. Forced expiratory volume in one second
(FEV1) was expressed as percentage of reference values.
2.6. Statistical analysis
Whole body and sub-regional body FFMI and BMD were
the primary outcomes of the study. We estimated that 72
patients (36 for each group) would be adequate to detect
a difference of 1 kg/m2 in whole body FFMI between
frequent and infrequent exacerbators (assumed SD = 1.5 kg/m2,
power = 80%, two-sided, α = 0.05).
Continuous data are presented as mean and SD, whereas
categorical data as counts and percentages. Comparisons
between groups were performed by means of Mann–Whitney
U test or Fisher exact test when appropriate. Spearman's rank
correlation coefficients were calculated to evaluate the associ-
ation between APEs and body composition, while Pearson's
correlation coefficients were computed to evaluate the associ-
ation between FEV1 and body composition data.
Multiple linear regression analysis was used to analyze
the association between variables controlling for potential
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chronic lung infections).
All statistical calculations were performed using the
Statistical Package for the Social Sciences (SPSS 15.0).
Significance was set at α b 0.05.
3. Results
3.1. Patients
We enrolled 85 patients [mean age 23 ± 4 years, range 18–
44 years, with 81(95%) patients younger than 30 years, 52%
males]. The frequency of pancreatic insufficiency was slightly
higher in males compared to females (P = 0.08), whereas the
prevalence of diabetes and pulmonary function was not
different between genders (P = 0.60 and P = 0.16, respective-
ly). During the year before DXA scan, 3 female patients
took systemic corticosteroids (2 patients received 25 mg/day of
prednisone for 30 days and 1 patient 25 mg/day for 50 days)
(Table 1).
3.2. Evaluation of nutritional status and body composition
Underweight was present in 12(14%) of the patients and was
more frequent in females [10(24%) vs. 2(5%), P = 0.009]. FFM
depletion was observed in 10(12%) of the patients. FFM
depletion was not recognized by standard anthropometric
measures (BMI b 18.5 kg/m2): 6(60%) out of the 10 patients
having FFM depletion had a BMI N 18.5 kg/m2. Sixty-two
patients (73%) had a BMI below the CFF nutritional goal and
52(61%) had a FFMI b 50th centile, with no significant
differences between genders (Table 1).Table 1
Patients' characteristics by gender.
Males (n = 44)
Age (years) 22.6 ± 3.3
Height (cm) 170 ± 7.5
Weight (kg) 63.4 ± 9.3
BMI (kg/m2) 21.8 ± 2.4
Underweight (BMI b18.5 kg/m2), n (%) 2 (5)
BMI below CFF nutritional goal, n (%) * 29 (66)
Pancreatic insufficiency, n (%) 40 (91)
Diabetes, n (%) 8 (18)
FEV1 (% of predicted) 69 ± 24
P. aeruginosa infection, n (%) 21 (48)
B. cepacia complex infection, n (%) 1 (2)
MRSA infection, n (%) 3 (7)
Oral corticosteroids, n (%) 0
BMC (g) 2306 ± 419
BMD (g/cm2) 1.153 ± 0.112
BMD (Z-score) −1.05 ± 1.14
FFM depletion (FFMI b5th centile), n (%) 8 (18)
FFMI b50th centile, n (%) 27 (61)
Abbreviations: BMI— Body Mass Index; CFF— Cystic Fibrosis Foundation; FEV
Staphylococcus aureus infection; BMC— total body Bone Mineral Content; BMD
body Fat Free Mass Index.
*Males b23 kg/m2, Females b22 kg/m2.3.3. Effect of pulmonary exacerbations on body composition
Forty-nine patients (58%) [22(45%) males and 27(66%)
females] experienced more than 2 APEs over the year that
preceded DXA scan and were defined as frequent exacerbators.
Among frequent exacerbators only male patients had lower
whole body and appendicular FFM compared to patients who had
a lower exacerbation rate. The reduced FFM found in frequent
exacerbators was not uniformly distributed and involved mainly
appendicular FFM (difference between means: −11% compared
to infrequent exacerbators, P = 0.016). Trunk FFM was not
significantly affected by APEs (difference between means: −3%
compared to infrequent exacerbators, P = 0.34) (Table 2). These
results were confirmed after adjusting the FFM for stature
(Fig. 1). Among male patients total body BMD was significantly
lower in frequent exacerbators compared to patients with a lower
exacerbation rate; these findings were even more relevant when
total body BMD was expressed as age and gender-specific
Z-score. In contrast, such differences were not found among
females (Table 2).
In males, the number of APEs that had occurred over the year
before DXA scan negatively correlated with Z-score of total body
BMD, whole body FFMI and appendicular FFMI (Table 3). A
trend towards lower BMI inmale patients who had higher APE rate
was observed (P = 0.067). Trunk FFMI did not significant
correlate with number of APEs (P = 0.30). In multiple linear
regression analysis the number of APEs over the year before
DXA scan remained significantly associated with Z-score of
total body BMD (β = −0.12, P = 0.008) and appendicular
FFMI (β = −0.15, P = 0.011), but not with whole body FFMI
(β = −0.19, P = 0.072) and BMI (β = −0.14, P = 0.32). No
significant associations were observed in females.Females (n = 41) All (n = 85) P value
24.4 ± 4.8 23.4 ± 4.2 0.099
161 ± 6.5 166 ± 8.4 b0.0001
53.1 ± 9.2 58.4 ± 10.6 b0.0001
20.5 ± 3 21.2 ± 2.8 0.001
10 (24) 12 (14) 0.009
33 (81) 62 (73) 0.15
31 (76) 71 (84) 0.08
10 (24) 18 (21) 0.60
63 ± 22 66 ± 23 0.16
19 (46) 40 (47) 1.00
3 (7) 4 (5) 0.35
2 (5) 5 (6) 1.00
3 (7) 3 (4) 0.11
1837 ± 263 1080 ± 422 b0.0001
1.041 ± 0.078 1.099 ± 0.113 b0.0001
−0.81 ± 1.03 −0.94 ± 1.09 0.38
2 (5) 10 (12) 0.091
25 (61) 52 (61) 1.00
1— Forced Expiratory Volume in one second; MRSA—Methicillin Resistan
— total body Bone Mineral Density; FFM— Fat Free Mass; FFMI— wholet
Table 2
Comparison of body composition data between frequent and infrequent exacerbators by gender.
Males Infrequent exacerbators (N = 22) Frequent exacerbators (N = 22)
Mean ± SD Mean ± SD % difference between means P value
Height (cm) 170 ± 6 170 ± 9 0% 0.97
Weight (kg) 65 ± 8 62 ± 10 −5% 0.29
BMI (kg/m2) 22.5 ± 2.3 21.2 ± 2.4 −6% 0.16
BMC (g) 2452 ± 312 2159 ± 466 −12% 0.024
BMD (g/m2) 1.190 ± 0.087 1.115 ± 0.129 −6% 0.029
Z-score −0.66 ± 0.92 −1.44 ± 1.22 −119% 0.033
Whole body FFM (kg) 56 ± 4.9 52.4 ± 7.7 −6% 0.082
Trunk FFM (kg) 27.1 ± 2.5 26.1 ± 3.6 −3% 0.34
Appendicular FFM (kg) 25.5 ± 2.5 22.6 ± 4.1 −11% 0.016
Whole body FFMI (kg/m2) 19.3 ± 1.4 18.0 ± 1.9 −7% 0.024
Appendicular FFMI (kg/m2) 8.8 ± 0.8 7.8 ± 1.0 −12% 0.004
Trunk FFMI (kg/m2) 9.3 ± 0.7 9.0 ± 1.0 −3% 0.49
Body Fat (%) 14.7 ± 4 15.4 ± 5.2 +5% 0.81
Females Infrequent exacerbators (N = 14) Frequent exacerbators (N = 27)
Height (cm) 161 ± 5 160 ± 7 −1% 0.74
Weight (kg) 54 ± 11 53 ± 8 −2% 0.90
BMI (kg/m2) 20.7 ± 4.1 20.4 ± 2.4 −2% 0.68
BMC (g) 1910 ± 267 1799 ± 257 −6% 0.20
BMD (g/m2) 1.064 ± 0.078 1.031 ± 0.077 −3% 0.29
Z-score −0.69 ± 0.99 −0.87 ± 1.06 −26% 0.48
Whole body FFM (kg) 39.1 ± 3.3 38.7 ± 4.7 −1% 0.56
Trunk FFM (kg) 20.1 ± 1.6 20.4 ± 2.7 +2% 0.96
Appendicular FFM (kg) 16.2 ± 1.4 15.5 ± 2.4 −4% 0.22
Whole body FFMI (kg/m2) 15.0 ± 1.2 15.0 ± 1.5 0% 0.86
Appendicular FFMI (kg/m2) 6.2 ± 0.6 6.0 ± 0.8 −3% 0.26
Trunk FFMI (kg/m2) 7.7 ± 0.7 7.7 ± 0.6 0% 0.90
Body Fat (%) 26.6 ± 7.4 26.2 ± 6.1 −2% 0.83
Abbreviations: BMI— Body Mass Index; BMC— total body Bone Mineral Content; BMD— total body Bone Mineral Density; FM— Fat Mass; FFM— Fat Free
Mass; FFMI— Fat Free Mass Index.
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males (R = −0.43, P = 0.004), but not in females (R = −0.28,
P = 0.075). The association between number of APEs and body
composition data was not independent of FEV1. FEV1 masked
the association between number of APEs and body composition
and after including FEV1 in the multiple linear regression model
no significant associations remained with whole body FFMI
(β = −0.03, P = 0.80), appendicular FFMI (β = −0.06, P =
0.29) and Z-score of total body BMD (β = −0.04, P = 0.57) in
males.3.4. Relationship between fat free mass and pulmonary function
FEV1 positively correlated with BMI, total body BMD,
whole body and appendicular FFMI, but not with trunk FFMI
(Table 4). These results were confirmed also adjusting for age,
diabetes, pancreatic insufficiency and chronic lung infections.
In multiple linear regression analysis BMI (β = 3.41, P =
0.007), whole body FFMI (β = 5.77, P b 0.0001), appendicu-
lar FFMI (β = 10.87, P b 0.0001), and Z-score of total body
BMD (β = 5.36, P = 0.023), remained significantly associated
with FEV1 in males. No significant associations were observed
in females.4. Discussion
The present study was designed to investigate the contribu-
tion of APEs on body composition alteration in young adults
with CF.
Our results clearly show that recurrent APEs are associated
with reduced FFM and BMD and that these alterations correlate
with worse pulmonary function. We found reduced FFM and
BMD in male patients who experienced more than two APEs
during the year before body composition evaluation. Moreover,
FFM depletion was not uniformly distributed, with a prevalent
impairment of appendicular FFM, while trunk FFM was not
affected.
However, a gender dependent relationship was found, and
these associations were not observed in females. This finding
disagrees with the results reported by King et al. who found
whole body FFMI to be positively associated with FEV1 also in
a group of 34 CF females [5]. This discrepancy may be
explained by the small number of subjects in the present and in
King's study and by the fact that FFM depletion was less
frequent in females compared to males, and this might have
affected the capacity to detect association between FFM and
pulmonary function in our study. Given the almost adequate
FFM of female patients, the relationship between FFM and
Fig. 1. Comparison of whole body and appendicular FFMI between frequent (N2 pulmonary exacerbations/year) and infrequent (≤2 pulmonary exacerbations/year)
exacerbators. Abbreviations: FFMI - Fat Free Mass Index; APE - Acute Pulmonary Exacerbation.
332 G. Alicandro et al. / Journal of Cystic Fibrosis 13 (2014) 328–334pulmonary function is less strong and harder to detect
compared to males. In addition we suppose that in females
other factors (such as earlier Pseudomonas aeruginosa
acquisition in females, delayed diagnosis and reduced physical
activity), that have been suggested to contribute to the gender
gap in survival, may overcome the possible effect of the
impaired nutritional status [13–15].
The anthropometric evaluation indicates a high prevalence
of undernutrition (14%) and DXA data shows FFM depletion in
a considerable proportion of our population (12%). This last
figure is similar to the results of King's et al., who found a
prevalence of FFM depletion of 14% among 86 adult CF
patients [5].
In agreement with previous studies, we found that standard
anthropometric evaluation was not useful in identifying patients
with FFM depletion [5,16].
Sustained inflammation compromises nutritional status in
patients with chronic diseases and can induce cachexia, a
condition that produces different metabolic response compared
to pure caloric depletion. During caloric depletion the organism
adapts to preserve body cell mass and increase fat metabolism,
while cachexia is associated with an inflammatory process andTable 3
Correlations between BMI or body composition data and pulmonary
exacerbations by gender.
APE 1 year before DXA scan
Males Females
BMI (kg/m2) −0.28 −0.08
Whole body FFMI (kg/m2) −0.40** −0.05
Appendicular FFMI (kg/m2) −0.52*** −0.20
Trunk FFMI (kg/m2) −0.16 0.05
Total body BMD (Z-score) −0.35* −0.25
Results are presented as Spearman's coefficients of correlation.
Abbreviations: APE — Acute Pulmonary Exacerbation; BMI — Body Mass
Index; FFMI: Fat Free Mass Index; BMD— Bone Mineral Density;
*** P b 0.001 ** P b 0.01 *P b 0.05.evokes an acute phase response, including increase degradation
of muscle proteins. BMI does not distinguish between body fat
and lean body mass and may not be a reliable nutritional index
when cachexia occurs.
APEs and chronic inflammation induce a catabolic state
with nitrogen imbalance and protein breakdown, all of which
can contribute to nutritional deterioration in CF. Cytokines
released during inflammation act on the central nervous system
to alter the release and function of a number of neurotransmit-
ters, thereby altering both appetite and metabolic rate [17,18].
The net result is sustained energy imbalance, a hard-to-treat
condition that causes poor nutritional status, a challenging
clinical issue in CF.
The preferential loss of appendicular FFM in frequent
exacerbators observed in the present study is of particular
interest and supports the findings of protein breakdown during
APE, reported in previous studies [19]. Regional body
composition analysis in CF has been previously performed by
Bolton et al. who found a hierarchical pattern of FFM loss in
CF, with limbs FFM more affected compared to trunk. Our
data, show that this pattern is even more severe in patients who
had recurrent APEs.Table 4
Correlations between BMI or body composition data and pulmonary function
by gender.
FEV1 (% of predicted)
Males Females
BMI (kg/m2) 0.47** 0.23
Whole body FFMI (kg/m2) 0.55*** 0.09
Appendicular FFMI (kg/m2) 0.64*** 0.06
Trunk FFMI (kg/m2) 0.29 −0.11
Total body BMD (Z-score) 0.38* 0.30
Results are presented as Pearson's coefficients of correlation.
Abbreviations: FEV1— Forced expiratory volume in 1 s; BMI— Body Mass
Index; FFMI: Fat Free Mass Index; BMD— Bone Mineral Density.
*** P b 0.001 ** P b 0.01 *P b 0.05.
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leg and arm, while visceral organs are the major components of
the trunk FFM. This consideration suggests that FFM of the
limbs is a better proxy of skeletal muscle mass and is a better
marker of muscle wasting, compared to trunk FFM.
Soft tissue analysis by DXA does not allow distinguishing
between muscles and viscera and does not evaluate skeletal
muscle mass. However, good correlation exists between
DXA-derived appendicular lean soft tissue and computed
tomography and magnetic resonance imaging-derived skeletal
muscle mass from the lower limb [20].
In Chronic Obstructive Pulmonary Disease a reduction in
FFM is a common finding, and is mainly related to muscle
wasting, indicating that whole body FFM depletion reflects
limb muscle atrophy [21,22]. Thus the asymmetrical pattern of
FFM depletion in our cohort, mainly involving the limbs, may
well reflect the specific effect of pulmonary disease on
muscular tissue. These considerations suggest the need to
include appendicular FFMI in nutritional monitoring of adult
CF patients.
In addition we showed that FFMI and BMI were associated
with better pulmonary function, with stronger association with
appendicular FFMI compared with trunk FFMI and BMI.
Recurrent APEs are associated with lung function deterio-
ration over time and are predictors of reduced survival in CF
patients [23,24]. In the present study recurrent APEs were
found to be associated with reduced FFM, a sensitive indicator
of nutritional status depletion, and with low FEV1, the main
predictor of survival in CF. These findings suggest that the two
main CF clinical outcomes (pulmonary function and nutritional
status) are linked to recurrent APEs that in turn are able to
sustain lung damage and impair nutritional status through a
catabolic response mediated by inflammation.
Reduced BMD is a common condition in CF and with
increased survival it is likely to become even more prevalent,
leading to poor quality of life and increased treatment burden
[25,26]. The etiology of decreased BMD in CF is multi-
factorial [25]. APEs affect BMD through overproduction of
pro-inflammatory cytokines and by stimulating the production
and activity of osteoclasts, resulting in increased bone
resorption [27,28].
Bone loss is among the adverse effects of glucocorticoid
therapy used to improve respiratory symptoms in CF patients.
In our population, only 3 patients took oral corticosteroids
1 year before body composition evaluation, therefore we were
unable to evaluate its effect on body composition alteration.
DXA is currently the gold standard method for measuring
bone mineral content and BMD and is also the most readily
available, useful technique for measuring body composition in
a clinical setting [20,26]. However it should be noted that it has
limitations that may have impacted on our findings. Some
concerns have been risen regarding the application of DXA to
determine body composition in medical research and clinical
practice. When DXA measurements of soft tissues were
compared to the 4-component model (the currently gold
standard approach to body composition analysis), a significant
bias was found for FM in healthy men, women and boys andfor FFM in healthy women, boys and girls, and girls with CF.
Moreover, DXA bias was shown to be related to body size,
fatness, type of disease (CF) and gender, with greater errors in
FFM (expressed as percentage of the mean value) in healthy
women and in CF girls in comparison with healthy men and CF
boys [29]. In addition a bias in FM was noted in girls and
adolescent females that cannot be attributed to ethnicity, age or
fatness [30].
Different chemical composition of FFM, swelling and
over-hydration, known as potential errors in FFM estimation,
may affect FFM value as determined by DXA. However, our
patients were all in stable conditions when performing DXA
and a significant error due to these reasons is unlikely.
However, DXA provides information on body composition
that, as shown in the present study, are related to clinical
outcomes in CF. Therefore, in view of low radiation exposure,
its use should be implemented in CF patients, not only to
monitor bone health, but also to evaluate body composition.
Limitations of the study include the lack of data on physical
activity, dietary intake and inflammatory markers. Moreover,
the retrospective design of our study did not allow measure-
ment of inflammatory markers that may have provided insight
on the inflammatory status in patients with frequent APEs. For
the same reason, we cannot exclude a potential selection bias.
However, the clinical characteristics of study subjects are not
different from those of the whole adult population followed in
2012 in our center (N = 145) in terms of age (mean age: 23.4
vs. 23.3 years), lung disease severity (15% of patients had
FEV b 40% in both groups) and nutritional status (14% in the
selected cohort vs. 17% of the whole 2012 population were
underweight). Finally, the adults patients followed in our clinic
are very young (about 80% had less than 30 years) and this
may limit the generalizability of our results to other adult
populations in which the number of adults N30 years may be
much greater.
In conclusion, APEs are negatively related to FFM and the
widely used anthropometric methods are not sufficient to
identify CF patients with depleted FFM. In CF patients,
a deeper evaluation, including also body composition, is
therefore recommended. The gender-dependent relationship
between APEs and body composition alteration observed in the
present study needs to be further investigated.4.1. Statement of authorship
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